Arcera Life Sciences
Arcera Life Sciences is an Abu Dhabi-based, ADQ-owned global pharmaceutical holding company consolidating Acino, Amoun Pharmaceutical, and Birgi Mefar Group to develop, manufacture, and commercialize 2,000+ medicines across 120+ markets, with EU GMP-certified manufacturing in eight countries and a portfolio spanning branded generics, innovative therapies, and contract manufacturing services.
- Company typePrivate
- Founded2024
- HeadquartersAbu Dhabi, United Arab Emirates
- Headcount5,001–10,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Arcera Life Sciences does
Arcera Life Sciences is a privately held global life sciences holding company headquartered in Abu Dhabi, United Arab Emirates, established by sovereign investor ADQ in 2024. The company consolidates three legacy pharmaceutical businesses — Acino (Swiss-founded, emerging markets specialty), Amoun Pharmaceutical Company (Egypt), and Birgi Mefar Group (Türkiye-based CDMO for sterile solutions and injectables) — under a unified operating model effective January 2025, organized into Arcera General Medicines and Arcera TechOps divisions.
The company develops, manufactures, and commercializes a portfolio of more than 2,000 branded medicines spanning oncology, neuroscience, cardiometabolic disease, rare diseases, and anti-infectives, with over 100 focus brands. Manufacturing and packaging operations span eight countries including EU GMP-certified facilities in Ukraine and Switzerland and ISO 14001-certified sites in Ukraine, South Africa, Türkiye, and Egypt. Notable products include Ariprazol (aripiprazole antipsychotic, EU-qualified with Latvia launch in 2026), a breakthrough intravenous antibiotic targeting antimicrobial resistance (UAE launch 2026), and the licensed AR1001 investigational Alzheimer's therapy. Arcera operates its own digital platforms, including the CATALYST AI-enabled decision intelligence platform for healthcare professional engagement and the IQVIA SmartSolve eQMS implemented across 12 locations.
The business model combines direct pharmaceutical product sales (reaching patients in 120+ markets), B2B contract manufacturing and out-licensing services (active in 75 countries), and licensing/supply agreements for innovative therapies. Revenue is generated across diverse customer segments including healthcare providers, government health systems, and pharmaceutical companies seeking emerging market access. Distribution combines direct enterprise sales (29 country offices) with channel/distribution partnerships, including a strategic collaboration with Fosun Pharma for Chinese biotech access and an MoU with M42 for biopharma localization in Abu Dhabi. Arcera employs approximately 6,000-6,500 people globally and operates with sovereign backing from ADQ, which is using the company as the anchor platform for Abu Dhabi's Healthcare Life Sciences Vision 2030.
Arcera Life Sciences firmographics
Firmographics- Name
- Arcera Life Sciences
- Legal name
- Arcera Life Sciences LLC OPC
- Website
- https://arceralifesciences.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Arcera Life Sciences is an Abu Dhabi-based, ADQ-owned global pharmaceutical holding company consolidating Acino, Amoun Pharmaceutical, and Birgi Mefar Group to develop, manufacture, and commercialize 2,000+ medicines across 120+ markets, with EU GMP-certified manufacturing in eight countries and a portfolio spanning branded generics, innovative therapies, and contract manufacturing services.
- Ownership category
- akta.pro rank
Arcera Life Sciences industry classification
Industry- Product category
- Pharmaceutical Manufacturing
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)
- akta.pro secondary industries
- Rare Cardiovascular & Vascular Disorder Therapies (HLAIAIAH), Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)
Keywords
Where Arcera Life Sciences is headquartered
LocationHeadquarters
- HQ city
- Abu Dhabi
- HQ country
- United Arab Emirates
- HQ region
- Middle East
Offices22 records
Markets served
Arcera Life Sciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Product Sales: Development, manufacturing, and commercialization of innovative and proven medicines across 2,000+ products, reaching patients in over 120 markets through direct sales and distribution networks.
- Contract Manufacturing Services: B2B contract manufacturing and out-licensing services to pharmaceutical companies, providing manufacturing capabilities across 8 countries including sterile solutions and injectables.
- Licensing and Supply Agreements: Revenue through exclusive licensing and supply agreements for innovative therapies, such as the AR1001 Alzheimer's treatment from AriBio and neuroscience collaborations with Fosun Pharma.
Go-to-market motion4 records
Distribution channels5 records
Marketing channels7 records
Arcera Life Sciences product offering
Product offeringCore offering
Arcera Life Sciences develops, manufactures, and commercializes over 2,000 branded generic and innovative pharmaceutical medicines across therapeutic areas including oncology, neuroscience, cardiometabolic, and rare diseases. The company operates through manufacturing facilities in eight countries and reaches patients in more than 120 markets via direct commercial operations, while also providing B2B contract manufacturing services to third-party pharmaceutical companies across 75 countries. Through licensing agreements and strategic partnerships, Arcera advances innovative therapies such as the AR1001 Alzheimer's treatment from AriBio.
Product overview
Arcera Life Sciences is a global pharmaceutical company headquartered in Abu Dhabi, established by ADQ. The company develops, manufactures, and commercializes over 2,000 branded medicines across multiple therapeutic areas. Arcera operates through three main subsidiaries: Acino, Amoun Pharmaceutical Company, and Birgi Mefar Group. The company offers products in branded generics, off-patent originator medicines, innovative medicines, and over-the-counter products, supported by manufacturing and packaging facilities in eight countries. The portfolio includes prescription pharmaceuticals (Ariprazol antipsychotic), anti-infectives (breakthrough AMR-targeting intravenous antibiotic), and the company leverages technology platforms including the CATALYST decision intelligence system and SmartSolve eQMS for operational excellence.
Differentiator
Problem solved
Functional benefit
Brands
- Ariprazol: Prescription antipsychotic medicine (aripiprazole) for treatment of schizophrenia and bipolar disorder.
- Arcera's AMR Antibiotic
Products and services
- Ariprazol (aripiprazole) Prescription antipsychotic medication indicated for the treatment of schizophrenia and bipolar disorder in adults, also used as part of broader therapeutic approaches for post-traumatic stress disorder. Received EU qualification release and launched commercially in Latvia with inclusion in Latvia's reimbursement program, manufactured at Acino Ukraine's EU GMP-certified facility.
- Breakthrough Intravenous Antibiotic for Antimicrobial Resistance (AMR) Intravenous antibiotic designed to restore efficacy against multidrug-resistant bacteria, including Extended Spectrum Beta-Lactamase-producing pathogens. Offers physicians a new treatment option against AMR, with UAE launch and regulatory approval progressing across GCC and registration plans for South Africa expected early 2027.
- Branded Generic and Innovative Medicines Portfolio Diversified portfolio of over 2,000 branded generic, off-patent originator, and innovative medicines across therapeutic areas including oncology, neuroscience, cardiometabolic diseases, and rare diseases. Reaches patients in 120+ markets across five continents through direct commercial operations and licensing agreements.
- Pharmaceutical Contract Manufacturing Services B2B contract manufacturing services for pharmaceutical companies requiring manufacturing capabilities for sterile solutions, injectables, and generic medicines. Services provided across 75 countries leveraging EU GMP-certified facilities in Switzerland, Ukraine, T\u00fcrkiye, South Africa, Egypt, and other locations.
- Pharmaceutical Licensing and Supply Services Exclusive licensing and supply agreements enabling pharmaceutical and biotech partners to commercialize therapies across multiple international markets. Examples include the AriBio AR1001 Alzheimer's therapy agreement and neuroscience collaborations with Fosun Pharma. Arcera provides regulatory, commercial, and market access expertise in emerging markets often not prioritized in early global launches.
Quantifiable outcome
- Over 40% of UAE portfolio sales from domestically manufactured products
- +3 more outcomes
Companies that use Arcera Life Sciences
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles4 records
Arcera Life Sciences technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature4 records
Arcera Life Sciences partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered flagship, core and supporting.
- M42flagshipM42 and Arcera signed a strategic MoU to advance biopharma localization, clinical development, and next-generation healthcare innovation in Abu Dhabi. The collaboration focuses on four pillars: genomics-informed therapeutic development, clinical development acceleration, advanced biobanking and regenerative medicine, and digital/AI-enabled transformation. Aligned with Department of Health Abu Dhabi's efforts to reinforce Emirate's position as a global hub for life sciences innovation.
- Emirates Drug Establishment (EDE)coreMoU to strengthen pharmaceutical manufacturing capabilities in UAE through collaboration on local manufacturing, talent development, research and innovation, and strategic supply of medical products. Partnership supports Emiratization through training programs, technical exchanges, and workshops. Contributes to expanding local manufacturing capacity and strengthening UAE's strategic stockpile of medical products.
- Fosun PharmaflagshipArcera and Fosun Pharma signed MoU for long-term strategic collaboration focused on licensing, frontier technology incubation, and neuroscience innovation. Initial focus on licensing opportunities in oncology, neuroscience, rare diseases, and cardiometabolic disease. Exploration of joint ventures to localize cutting-edge biotechnology including biologics, radiopharmaceuticals, siRNA therapies, and cell and gene therapies in UAE. Aligned with China-UAE bilateral partnership and Abu Dhabi's Healthcare Life Sciences Vision 2030.
- IQVIAsupportingPartnership for implementation of new electronic Quality Management System (eQMS) consisting of six SmartSolve modules across 12 locations and corporate functions. Successfully implemented in nine months, strengthening quality, efficiency, and collaboration across manufacturing network.
- NYU Abu DhabisupportingAcademic partner hosting Arcera's Catalyst Forum at NYU Abu Dhabi, bringing together healthcare, academic, government, and industry leaders to discuss AI-powered healthcare transformation.
- Department of Health Abu DhabicoreCollaboration through M42 partnership framework to leverage genomics data, support clinical development, and align with DoH's efforts to reinforce Abu Dhabi as global hub for life sciences innovation.
- ISPOR UAE ChaptercoreStrategic MoU to advance health economics and outcomes research (HEOR) and health technology assessment (HTA) in UAE. Partnership focuses on enhancing research capabilities, building national expertise, and supporting evidence-based decision-making. Also includes collaboration on capacity building, career development, and mentorship. Supports UAE's ambition for healthcare excellence and life sciences leadership.
- AriBiocoreExclusive licensing and supply agreements for AR1001, an investigational therapy for Alzheimer's disease. Arcera will advance development and commercialize the therapy across multiple international markets. Collaboration reflects commitment to identifying promising therapies and accelerating patient access in markets often not prioritized in early stages of global product launches.
- AribiocoreExclusive licensing and supply agreements for AR1001, an investigational therapy for Alzheimer's disease. Arcera will advance development and commercialize across multiple international markets, particularly emerging markets not prioritized in early global launches.
- LG ChemsupportingExclusive agreement for marketing, commercialization, and distribution of Hyruan One in Brazil for osteoarthritis treatment, and Zemiglo and Zemimet SR (Zemiduo SR in Mexico) for type 2 diabetes in Latin American markets.
Scale indicators11 records
Recent moves6 records
Expansion highlights6 records
Arcera Life Sciences competitors and assessment
Company assessmentDirect peers
- Aurobindo Pharma: Indian generic and specialty pharmaceutical company with strong emerging markets footprint. Comparable through large-scale branded generics, complex injectables manufacturing, and emerging markets distribution capability.
- Aspen Pharmacare: South African pharmaceutical leader with operations across Africa, Latin America, and Asia. Comparable to Arcera through its emerging markets focus, branded generics portfolio, and complex manufacturing footprint in multiple jurisdictions.
- Cipla: Indian pharmaceutical major with strong presence in Africa, emerging markets, and respiratory/chronotherapeutics. Directly comparable through its emerging markets commercial infrastructure, branded generics model, and ARV/oncology therapeutic focus areas.
- Hikma Pharmaceuticals: Jordan-headquartered branded generics and injectables manufacturer with deep MEA and emerging markets presence. Directly comparable to Arcera through similar geographic focus, branded generics portfolio, and CDMO/injectables capabilities.
- Dr. Reddy's Laboratories: Indian global pharmaceutical company with significant emerging markets presence across CIS, Africa, and Latin America. Comparable through diversified branded generics portfolio, CDMO services, and biosimilars pipeline.
- Julphar (Gulf Pharmaceutical Industries): UAE-headquartered pharmaceutical manufacturer with MEA regional focus. Directly comparable to Arcera as the most prominent homegrown UAE pharma player with similar GCC distribution model and branded generics portfolio.
- Lupin Pharmaceuticals: Indian pharmaceutical company with branded generics, complex generics, and biosimilars portfolio across emerging markets. Comparable through similar therapeutic focus areas and emerging markets commercial model.
Broad incumbents
- Teva Pharmaceutical Industries: Global leader in generics and specialty medicines with extensive emerging markets presence. Comparable through broad generics portfolio and complex manufacturing, though operates at significantly larger scale and is publicly listed.
- Sandoz (Novartis): Global generics and biosimilars business carved out of Novartis with worldwide distribution. Comparable through diversified generics portfolio and biologics manufacturing capabilities, though Sandoz is a global incumbent with much broader geographic reach.
- Viatris: Global generics and biosimilars giant formed from Mylan-Upjohn merger with worldwide reach. Comparable through branded generics and off-patent originator medicines focus, though Viatris operates at much larger global scale across all major markets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
Arcera Life Sciences social profiles
Digital presenceArcera Life Sciences compliance and trust
Trust signalCompliance3 records
Arcera Life Sciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Arcera Life Sciences leadership team
Management profileNumber of profiles
Profiles17 records
Arcera Life Sciences subsidiaries and ownership
Company hierarchySubsidiaries14 records
Arcera Life Sciences funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Arcera Life Sciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Arcera Life Sciences
What does Arcera Life Sciences do?
Arcera Life Sciences develops, manufactures, and commercializes over 2,000 branded generic and innovative pharmaceutical medicines across therapeutic areas including oncology, neuroscience, cardiometabolic, and rare diseases. The company operates through manufacturing facilities in eight countries and reaches patients in more than 120 markets via direct commercial operations, while also providing B2B contract manufacturing services to third-party pharmaceutical companies across 75 countries. Through licensing agreements and strategic partnerships, Arcera advances innovative therapies such as the AR1001 Alzheimer's treatment from AriBio.
Is Arcera Life Sciences a public or private company?
Arcera Life Sciences is a private company. It is classified as corporate owned and is currently operating.
When was Arcera Life Sciences founded?
Arcera Life Sciences was founded in 2024. It employs 5,001 to 10,000 people.
Where is Arcera Life Sciences based?
Arcera Life Sciences is headquartered in Abu Dhabi, United Arab Emirates, in the Middle East region.
How does Arcera Life Sciences make money?
Three revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are contract Manufacturing Services and licensing and Supply Agreements.
Who are Arcera Life Sciences's main competitors?
Direct peers on record are Aurobindo Pharma, Aspen Pharmacare, Cipla, Hikma Pharmaceuticals, Dr. Reddy's Laboratories, Julphar (Gulf Pharmaceutical Industries) and Lupin Pharmaceuticals. Broad incumbents are Teva Pharmaceutical Industries, Sandoz (Novartis) and Viatris.
Does Arcera Life Sciences have an API?
No public API is recorded for Arcera Life Sciences.
What industry is Arcera Life Sciences in?
Arcera Life Sciences's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of HLAIAIAH, Rare Cardiovascular & Vascular Disorder Therapies. Its NAICS code is 3254 and its SIC code is 2834.